Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | SHB-02-CD19 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on SHB-02-CD19, putative chimeric antigen receptor (CAR) T-cells targeting CD19 (Apr 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| SHB-02-CD19 | SHB02-CD19|SHB 02CD19 | CD19 Immune Cell Therapy 76 | Limited information is currently available on SHB-02-CD19, putative chimeric antigen receptor (CAR) T-cells targeting CD19 (Apr 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT07503353 | Phase Ib/II | SHB-02-CD19 | A Phase 1/2 Study of T-cell Expressing a Novel CD19 Chimeric-Antigen Receptor (SHB-02-CD19) in Patients With CD19-expressing B-cell Malignancies | Not yet recruiting | ISR | 0 |